Register Now: From Clinical to Commercial: Accelerating ADC Late-Stage Development with Technology Innovation and Integrated Platform
|Articles|May 10, 2017

PhRMA Increases R&D Criteria for Member Companies

More stringent R&D investment requirements for PhRMA membership reduces the association ranks by 22 associate and member companies.

The Pharmaceutical Research and Manufacturers of America (PhRMA) has revised its membership criteria, increasing research and development requirements for eligible member companies. The board of directors of the association announced the immediate change in membership definitions in an announcement on May 9, 2017.

The board eliminated the associate membership category and now requires eligible members to have a three-year average global R&D to global sales ratio of 10% or greater; and aa three-year average global R&D spending of at least $200 million per year. Following the announcement, the association’s website listed 37 member companies.

Under the new policies, 15 associate member companies and seven full member companies are no longer eligible for membership; however, the companies can reapply for membership when they meet the criteria, according to an association statement.

“By putting in place new membership criteria, the board is sending a clear message that being a member of PhRMA means being committed to doing the time-intensive, scientifically sound research it takes to bring bold new advances in treatments and cures to patients,” said Joaquin Duato, PhRMA board chairman and worldwide chairman, pharmaceuticals, Johnson & Johnson in a PhRMA statement.

Source: Pharmaceutical Research and Manufacturers of America (PhRMA)


Related to this article

The BioPharm Brief: Cosentyx Approved in Polymyalgia Rheumatica, a Phase 3 Survival Win for an AML Vaccine, and $173 Million for In Vivo Bone Marrow Editing
FDA approves Novartis’ Cosentyx as the first anti-IL-17 biologic for polymyalgia rheumatica, SELLAS Life Sciences’ WT1-targeted peptide vaccine galinpepimut-S meets its overall survival primary endpoint in the phase 3 REGAL trial in AML, and Marrow Therapeutics launches with $173 million to develop bone marrow-targeted genetic medicines.